###begin article-title 0
M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis
###end article-title 0
###begin p 1
###xml 721 734 721 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">osteopetrotic</italic>
###xml 736 741 736 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 816 817 816 817 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 827 828 827 828 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 743 747 <span type="species:ncbi:10090">mice</span>
###xml 1046 1051 <span type="species:ncbi:10090">mouse</span>
Antiangiogenic therapy for the treatment of cancer and other neovascular diseases is desired to be selective for pathological angiogenesis and lymphangiogenesis. Macrophage colony-stimulating factor (M-CSF), a cytokine required for the differentiation of monocyte lineage cells, promotes the formation of high-density vessel networks in tumors and therefore possesses therapeutic potential as an M-CSF inhibitor. However, the physiological role of M-CSF in vascular and lymphatic development, as well as the precise mechanisms underlying the antiangiogenic effects of M-CSF inhibition, remains unclear. Moreover, therapeutic potential of M-CSF inhibition in other neovascular diseases has not yet been evaluated. We used osteopetrotic (op/op) mice to demonstrate that M-CSF deficiency reduces the abundance of LYVE-1+ and LYVE1- macrophages, resulting in defects in vascular and lymphatic development. In ischemic retinopathy, M-CSF was required for pathological neovascularization but was not required for the recovery of normal vasculature. In mouse osteosarcoma, M-CSF inhibition effectively suppressed tumor angiogenesis and lymphangiogenesis, and it disorganized extracellular matrices. In contrast to VEGF blockade, interruption of M-CSF inhibition did not promote rapid vascular regrowth. Continuous M-CSF inhibition did not affect healthy vascular and lymphatic systems outside tumors. These results suggest that M-CSF-targeted therapy is an ideal strategy for treating ocular neovascular diseases and cancer.
###end p 1
###begin p 2
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 284 285 284 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 436 437 436 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">3</xref>
###xml 438 439 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 556 557 556 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 559 560 559 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 645 646 645 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 808 809 808 809 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 921 922 921 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 923 925 923 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 1145 1147 1145 1147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
###xml 798 806 <span type="species:ncbi:9606">patients</span>
Pathological angiogenesis is a hallmark of cancer and various inflammatory conditions including ocular neovascular diseases (1, 2). Recent studies have led to the discovery of a growing number of antiangiogenic molecules, some of which are already being evaluated in clinical trials (1, 2). The most established approach for limiting pathological angiogenesis involves blockade of the vascular endothelial growth factor (VEGF) pathway (3-5); however, several studies have shown that VEGF blockade damages healthy vessels and results in toxic side effects (6, 7) and that interrupting the VEGF blockade induces rapid vascular regrowth in tumors (8). Clinical trials involving patients with neovascular age-related macular degeneration have shown that VEGF blockade has limited effectiveness in some patients (5). Therefore, several groups have explored other targets that could potentially be combined with VEGF blockade (9-11). In particular, tumor-associated hematopoietic cells are thought to be a promising therapeutic target, especially neutralizing Bv8, which promotes both tissue-specific angiogenesis and hematopoietic cell mobilization (10).
###end p 2
###begin p 3
###xml 24 26 24 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 180 182 180 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 259 272 259 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">osteopetrotic</italic>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 327 332 327 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csf-1</italic>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 620 622 620 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib17">17</xref>
###xml 796 798 796 798 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 887 889 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 288 292 <span type="species:ncbi:10090">mice</span>
###xml 300 304 <span type="species:ncbi:10090">mice</span>
###xml 585 590 <span type="species:ncbi:10090">mouse</span>
###xml 752 757 <span type="species:ncbi:9606">human</span>
###xml 786 790 <span type="species:ncbi:10090">mice</span>
Macrophage CSF (M-CSF) (12) is a cytokine required for the differentiation of monocyte lineage cells (e.g., tissue macrophages, osteoclasts, and microglia) during development (13, 14). Although greatly reduced numbers of monocyte lineage cells are present in osteopetrotic (op/op) mutant mice (i.e., mice that possess a mutant csf-1 gene encoding M-CSF) (13), the potential effects on angiogenesis and lymphangiogenesis have not been evaluated. Recent studies suggest that M-CSF plays a key role in the formation of high-density vessel networks and acts as an "angiogenic switch" in a mouse model of mammary tumors (15, 16). The inhibition of M-CSF by antisense oligonucleotides, small interfering RNAs, or blocking antibodies suppresses the growth of human mammary tumor xenografts in mice (17, 18). Clodronate liposome, a reagent for depleting macrophages, also inhibits tumor growth (19). However, the mechanisms underlying the role of M-CSF in tumor progression, particularly with regards to tumor lymphangiogenesis and tumor selectivity, have not been fully dissected.
###end p 3
###begin p 4
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 435 443 <span type="species:ncbi:9606">patients</span>
###xml 537 542 <span type="species:ncbi:9606">human</span>
Osteosarcoma, the most common primary bone tumor, is defined as a malignant tumor derived from mesenchymal or stromal cells with highly metastatic capacities, particularly in the lung and liver (20). Multimodal treatment, often consisting of aggressive chemotherapy combined with radical surgical resection (e.g., limb amputation), has traditionally been the mainstay of osteosarcoma management; however, the prognosis of osteosarcoma patients has not improved significantly in recent years (20). Lack of an appropriate animal model for human osteosarcoma has hampered the development of an effective antiosteosarcoma therapy.
###end p 4
###begin p 5
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 29 33 <span type="species:ncbi:10090">mice</span>
###xml 307 312 <span type="species:ncbi:10090">mouse</span>
In this study, we used op/op mice to demonstrate that M-CSF contributes to both vascular and lymphatic development. Furthermore, our data show that M-CSF is required for retinal pathological neovascularization but not for the maintenance of stable adult vasculature or lymphatics. Using a newly established mouse model of osteosarcoma, we show that M-CSF inhibition selectively suppresses tumor angiogenesis and lymphangiogenesis. In contrast to VEGF blockade, the interruption of M-CSF inhibition does not promote rapid tumor regrowth. These findings indicate that M-CSF-targeted therapy is an ideal strategy for the treatment of ocular neovascular diseases and cancer.
###end p 5
###begin title 6
RESULTS
###end title 6
###begin title 7
M-CSF contributes to developmental vascular remodeling but not to maintenance of adult vasculature
###end title 7
###begin p 8
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
###xml 411 419 411 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 640 648 640 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 709 717 709 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
###xml 819 827 819 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 952 960 952 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 E</xref>
###xml 1019 1027 1019 1027 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 F</xref>
###xml 1283 1285 1283 1285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 1376 1378 1376 1378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib25">25</xref>
###xml 1592 1597 1592 1597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1674 1689 1674 1689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, G and H</xref>
###xml 1768 1773 1768 1773 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1782 1801 1782 1801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, A, B, and K</xref>
###xml 1889 1891 1889 1891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 1938 1946 1938 1946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 J</xref>
###xml 1973 1978 1973 1978 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 2101 2120 2101 2120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, C, D, and K</xref>
###xml 2157 2162 2157 2162 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 2205 2213 2205 2213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 K</xref>
###xml 2258 2263 2258 2263 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 2404 2409 2404 2409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 2462 2477 2462 2477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, E and F</xref>
###xml 2515 2523 2515 2523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2 I</xref>
###xml 2546 2551 2546 2551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 2618 2623 2618 2623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 2675 2690 2675 2690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, G and H</xref>
###xml 2881 2883 2881 2883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 2960 2962 2960 2962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 3167 3178 3167 3178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, L&#8211;P</xref>
###xml 3369 3374 3369 3374 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 3525 3536 3525 3536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2, L&#8211;P</xref>
###xml 1598 1602 <span type="species:ncbi:10090">mice</span>
###xml 1932 1936 <span type="species:ncbi:10090">mice</span>
###xml 2163 2167 <span type="species:ncbi:10090">mice</span>
###xml 2772 2776 <span type="species:ncbi:10090">mice</span>
###xml 3121 3125 <span type="species:ncbi:10090">mice</span>
###xml 3133 3137 <span type="species:ncbi:10090">mice</span>
Postnatal retinal vascular development, a widely used model for studying sprouting angiogenesis, can be used to study pathological angiogenesis (e.g., the formation of blood vessels in tumors) (21, 22). We first characterized macrophages in a retinal angiogenesis model. Macrophages stained with Mac-1 were found in avascular and vascularized areas and were readily distinguished from desmin-stained pericytes (Fig. 1 A). Active vascular remodeling takes place in capillary areas during the pruning of vascular capillary components (23). Macrophages in these areas had large expanded cytoplasms and contained vesicles positive for PECAM-1 (Fig. 1 B) in contrast to the lean bodies observed in arterial areas (Fig. 1 C). Immunostaining of laminin revealed the presence of basal lamina between macrophages and pericytes (Fig. 1 D). We then examined several angiogenic factors and were unable to detect VEGF in macrophages via in situ hybridization (ISH; Fig. 1 E). Furthermore, abundant matrix metalloproteinase (MMP) 9 (Fig. 1 F) and MMP-2 (not depicted) expression was detected on the cell surfaces of macrophages. Both of these MMPs are macrophage-derived proteases that work with modulating extracellular matrix (ECM) proteins, such as fibronectin, to remodel vascular structures (24). Macrophages contribute to programmed cell death in temporary hyaloid vessels via Wnt7b (25); however, their role in the formation of retinal vascular plexus has not yet been clarified. Therefore, we examined the role of M-CSF in developmental angiogenesis by examining the retinal vascular structures of op/op mice, which lack macrophages stained with Mac-1, F4/80, CD45, or isolectin (Fig. 1, G and H). By postnatal day (P) 2, branching was reduced in the vascular plexus of the op/op retina (Fig. 2, A, B, and K), but the numbers of endothelial tip cells and filopodia (which are regulated by VEGF [26]) were comparable to those in wild-type mice (Fig. 2 J). Vascular defects in the op/op retina were also detected on P4, as shown by significantly reduced branching and insufficient arterial-venous patterning (Fig. 2, C, D, and K). The reduced branching observed in op/op mice recovered as development progressed (Fig. 2 K and ). 3 mo after birth, the vasculature of op/op retinas was comparable to that in +/+ retinas (Fig. S1, C and D). We then investigated the mechanisms underlying vascular impairment in the op/op retina. Although VEGF expression remained the same (Fig. 2, E and F), the expression of MMP-2 and MMP-9 (Fig. 2 I) was decreased in the op/op retina. Presumably because of this decreased proteinase activity, op/op retina showed disordered fibronectin architecture (Fig. 2, G and H). To examine the function of M-CSF in the postnatal developing retina, wild-type mice were systemically treated with a small molecule tyrosine kinase inhibitor specific for c-fms (Ki20227) (27) or intraocularly injected with anti-c-fms neutralizing antibodies (AFS98) (28) during the postnatal stage. Both treatments significantly reduced branching by P4, but the number of endothelial tip cells was comparable to that in control mice (i.e., mice treated with vehicle alone) (Fig. 2, L-P). The reduction rate for branching points was greater in response to M-CSF inhibition than in response to M-CSF deficiency, suggesting that some form of compensation occurs in the postnatal op/op retina. When retinas were treated with Ki20227/anti-c-fms antibodies, macrophages decreased in number and exhibited insufficient stellate morphology (Fig. 2, L-P). Thus, these results suggest that M-CSF contributes to developmental vascular remodeling independently of VEGF but does not contribute to the maintenance of adult vasculature.
###end p 8
###begin p 9
###xml 0 57 0 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Characterization of macrophages in the developing retina.</bold>
###xml 1464 1469 1464 1469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1567 1568 1565 1566 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1470 1474 <span type="species:ncbi:10090">mice</span>
Characterization of macrophages in the developing retina. (A-C) Triple immunohistochemistry (IHC) of Mac-1 (green), desmin (red), and PECAM-1 (blue) within the P4 retina (representative images of three independent experiments). Macrophages in the venous/capillary (v) area possessed largely expanded cytoplasms and contained vesicles positive for PECAM-1 (B) in contrast to their lean bodies in the arterial area (a; C). (D) Triple IHC of Mac-1 (green), desmin (red), and laminin (blue; a representative image of three independent experiments). Macrophages (closed arrowheads) were identified in the perivascular space outside the basement membrane, whereas pericytes (arrows) and circulating monocytes (open arrowheads) were identified inside the basement membrane. (E) An ISH analysis of VEGF (purple) combined with isolectin B4 staining (green) of P4 (a representative image of six independent experiments). Macrophages (arrowheads) did not express VEGF, whereas astrocytes abundantly expressed VEGF. (F) An IHC analysis of MMP-9 (red) combined with isolectin B4 staining (blue; representative images of three independent experiments). MMP-9 was abundantly expressed in macrophages (arrowheads). (G) Double IHC of isolectin B4 (blue) and Mac-1, CD45, or F4/80 (green, as indicated) at P4 (representative images of eight independent experiments). Note that perivascular cells stained with Mac-1, CD45, F4/80, or isolectin were all identical and were absent from op/op mice. (H) Quantification of perivascular cells (mean +/- SD) stained with Mac-1, CD45, or F4/80 (n = 8). Bars, 50 microm.
###end p 9
###begin p 10
###xml 0 55 0 55 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M-CSF contributes to developmental vascular remodeling.</bold>
###xml 328 333 328 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 538 543 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 630 635 630 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 927 932 927 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1038 1043 1038 1043 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1212 1213 1210 1211 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1274 1275 1270 1271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1878 1879 1872 1873 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1932 1933 1926 1927 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 544 548 <span type="species:ncbi:10090">mice</span>
###xml 636 640 <span type="species:ncbi:10090">mice</span>
###xml 933 937 <span type="species:ncbi:10090">mice</span>
###xml 1044 1048 <span type="species:ncbi:10090">mice</span>
###xml 1683 1687 <span type="species:ncbi:10090">mice</span>
M-CSF contributes to developmental vascular remodeling. (A-D) An IHC analysis of PECAM-1 in P2 (A and B) and P4 (C and D) retinas (representative images of seven independent experiments). Note the reduced branching at P2 (indicated by arrowheads in B) and insufficient arterio-venous (a and v, respectively) patterning at P4 in op/op mice. (E and F) An ISH analysis of VEGF (purple) combined with isolectin B4 staining (green) at P4 (representative images of three independent experiments). VEGF expression (asterisks) was not altered in op/op mice. Also note the insufficient arterio-venous (a and v, respectively) patterning in op/op mice. (G and H) Double IHC of PECAM-1 (blue) and fibronectin (green) at P4 (representative images of four independent experiments). Note the irregular fibronectin proteins excessively deposited around the endothelial tubes (arrowheads) and rounded debris in the parenchymal area (arrows) in op/op mice. (I) Western blots of MMP-2 and MMP-9 in the P4 retina. Expression of MMP-2 and -9 decreased in the op/op mice. Representative panels are shown from three independent experiments. (J) The number of tip cells and filopodia (mean +/- SD) were quantified as shown on the left (n = 7). (K) Quantification (mean +/- SD) of branching points (n = 7). (L-O) Double IHC of Mac-1 (green) and PECAM-1 (blue) in P4 retinas after systemic treatment with vehicle (L) or Ki20227 (M) during P1-P4 or after intraocular injection with control IgG (N) or anti-c-fms IgG (O) at P1 (representative images of seven independent experiments). Note reduced branching points (yellow dots) and unaffected tip cells (red dots) in Ki20227-treated and anti-c-fms IgG-treated mice. Macrophages in retinas treated with Ki20227 and anti-c-fms antibodies exhibited insufficient stellate morphology and were present in lower numbers. (P) Quantification (mean +/- SD) of Mac-1+ perivascular cells, tip cells, or branching points (n = 7). Bars, 50 microm. *, P < 0.05; **, P < 0.01.
###end p 10
###begin title 11
M-CSF is required for pathological neovascularization but not for recovery of normal vasculature in oxygen-induced retinopathy (OIR)
###end title 11
###begin p 12
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 261 263 261 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 735 743 735 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 A</xref>
###xml 770 775 770 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csf-1</italic>
###xml 776 783 776 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> vegf-a</italic>
###xml 809 815 809 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csfr-1</italic>
###xml 874 885 874 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, B&#8211;D</xref>
###xml 901 907 901 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csfr-1</italic>
###xml 949 950 949 950 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 969 970 969 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 978 986 978 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3 E</xref>
###xml 1005 1011 1005 1011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csfr-1</italic>
###xml 1070 1076 1070 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csfr-1</italic>
###xml 1226 1231 1226 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1345 1350 1345 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1487 1492 1487 1492 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1590 1607 1590 1607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, F&#8211;I and V</xref>
###xml 1948 1965 1948 1965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, J&#8211;O and V</xref>
###xml 2105 2110 2105 2110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 2117 2128 2117 2128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, R&#8211;U</xref>
###xml 2177 2180 2177 2180 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 2443 2462 2443 2462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3, P, Q, and V</xref>
###xml 60 64 <span type="species:ncbi:10090">mice</span>
###xml 393 399 <span type="species:ncbi:9606">humans</span>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
###xml 1672 1676 <span type="species:ncbi:10090">mice</span>
###xml 1906 1910 <span type="species:ncbi:10090">mice</span>
###xml 2042 2046 <span type="species:ncbi:10090">mice</span>
###xml 2111 2115 <span type="species:ncbi:10090">mice</span>
###xml 2181 2185 <span type="species:ncbi:10090">mice</span>
Although normalized vasculature in the later stage of op/op mice suggests that M-CSF is not required for the maintenance of stable adult vasculature, we suspected that M-CSF might be critical for the induction of pathological neovascularization. The OIR model (29) is a widely used system to examine ocular neovascularization, a condition which resembles proliferative diabetic retinopathy in humans (30). In this model, the central area of established vasculature is obliterated by hyperoxic insult, creating an ischemic area. After mice are returned to room air, revascularization occurs and the normal vasculature is recovered, although some vessels (i.e., neovascular tufts [NVTs]) proliferate abnormally toward the vitreous body (Fig. 3 A). Increased expression of csf-1, vegf-a, and the c-fms receptor (csfr-1) was observed during neovascularization in the OIR model (Fig. 3, B-D). In addition, csfr-1 expression was higher in FACS-sorted Mac1+ cells than in Mac1- cells (Fig. 3 E), suggesting that csfr-1 is specific to macrophages. These data also indicate that csfr-1 expression in tissues largely reflects the number of macrophages. There was no significant difference in the vaso-obliterated areas of wild-type and op/op retina on P11 in the OIR model (), suggesting that vascular resistance to hyper oxygen insult was not altered in op/op retina. Similarly, Ki20227 treatment did not alter vascular resistance to hyper oxygen insult (Fig. S2, C, D, G, H, and J). On P16, the op/op retina exhibited a dramatic decrease in NVTs but an increase in physiological revascularization (Fig. 3, F-I and V). To confirm the role of M-CSF in neovascularization, wild-type mice were systemically treated with Ki20227 or intraocularly injected with anti-c-fms neutralizing antibodies during neovascularization. Both avascular and NVT areas dramatically decreased in response to these treatments, relative to mice treated with vehicle or control IgG (Fig. 3, J-O and V). The number of macrophages surrounding NVT areas dramatically decreased in mice treated with Ki20227/anti-c-fms antibodies, as well as in op/op mice (Fig. 3, R-U [quantification not depicted]). Retinas in MMP-9-/- mice exhibited significantly fewer NVTs but increased physiological revascularization (unpublished data). In contrast, treatment with SU1498, a potent and selective inhibitor of VEGFR2, nonselectively suppressed both pathological and physiological angiogenesis (Fig. 3, P, Q, and V). Collectively, these data suggest that targeting macrophage/ECM-related molecules selectively inhibits pathological neovascularization but does not affect the recovery of normal vasculature in the OIR model.
###end p 12
###begin p 13
###xml 0 108 0 108 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M-CSF is required for pathological neovascularization but not for the recovery of normal vasculature in OIR.</bold>
###xml 484 490 482 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf-a</italic>
###xml 496 502 494 500 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csfr-1</italic>
###xml 511 516 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csf-1</italic>
###xml 591 592 589 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 731 737 727 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csfr-1</italic>
###xml 758 759 754 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 768 769 764 765 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 819 820 815 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1004 1009 1000 1005 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1376 1381 1372 1377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1583 1584 1577 1578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 305 309 <span type="species:ncbi:10090">mice</span>
###xml 1010 1014 <span type="species:ncbi:10090">mice</span>
###xml 1029 1033 <span type="species:ncbi:10090">mice</span>
###xml 1103 1107 <span type="species:ncbi:10090">mice</span>
M-CSF is required for pathological neovascularization but not for the recovery of normal vasculature in OIR. (A) Isolectin staining of retinas in an OIR model. The central area of established vasculature was obliterated by hyperoxic insult, resulting in an avascular area (asterisks). After returning the mice to room air, normal vasculature was recovered via revascularization (arrows), although NVTs proliferated toward the vitreous body. (B-D) Relative expression (mean +/- SD) of vegf-a (B), csfr-1 (C), or csf-1 (D) in retinal tissues exposed to normoxic conditions or in an OIR model (n = 5; all experiments were performed in quadruplicate and the mean for each sample was obtained). (E) Relative expression (mean +/- SD) of csfr-1 in FACS-sorted Mac-1+ or Mac-1- cells obtained from P16 retinas in an OIR model (n = 5). (F-Q) Isolectin staining of P16 retinas in an OIR model (representative images of six independent experiments). Note the decreased avascular area (yellow) and NVT area (red) in op/op mice (H and I) and mice systemically treated with Ki20227 (L and M) during P12 and P16 or in mice that were given intraocular anti-c-fms antibodies during P12 (N and O). Systemic treatment with SU1498 decreased NVT area and increased avascular area (P and Q). (R-U) Double IHC of Mac-1 (green) and isolectin (blue) in the P16 retinas of an OIR model. Macrophages in op/op retinas or retinas treated with Ki20227/anti-c-fms antibodies were reduced in number and exhibited insufficient stellate morphology. (V) Quantification (mean +/- SD) of the avascular area or NVT area (n = 6). Bars, 200 microm. *, P < 0.05; **, P < 0.01.
###end p 13
###begin title 14
M-CSF contributes to postnatal lymphatic development
###end title 14
###begin p 15
###xml 201 202 201 202 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 325 326 325 326 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 362 363 362 363 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 392 393 392 393 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 442 453 442 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, A&#8211;C</xref>
###xml 513 514 513 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 529 530 529 530 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 544 552 544 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 D</xref>
###xml 679 684 679 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 719 720 719 720 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 731 732 731 732 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 796 801 796 801 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 854 875 854 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, E&#8211;H, O, and P</xref>
###xml 950 955 950 955 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 962 973 962 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, I&#8211;L</xref>
###xml 989 994 989 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1063 1078 1063 1078 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, E and F</xref>
###xml 1212 1217 1212 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1238 1240 1238 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 1299 1304 1299 1304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1392 1397 1392 1397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1465 1466 1465 1466 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1480 1495 1480 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, M and N</xref>
###xml 1573 1574 1573 1574 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1585 1586 1585 1586 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1646 1661 1646 1661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, R and S</xref>
###xml 1744 1745 1744 1745 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 685 689 <span type="species:ncbi:10090">mice</span>
###xml 802 806 <span type="species:ncbi:10090">mice</span>
###xml 956 960 <span type="species:ncbi:10090">mice</span>
###xml 995 999 <span type="species:ncbi:10090">mice</span>
###xml 1218 1222 <span type="species:ncbi:10090">mice</span>
###xml 1305 1309 <span type="species:ncbi:10090">mice</span>
###xml 1398 1402 <span type="species:ncbi:10090">mice</span>
Macrophages are thought to play important roles in lymphangiogenesis, particularly in macrophage subpopulations that express LYVE-1, a marker of lymphatics. In these subpopulations, the number of LYVE1+ macrophages correlate with the extent of tissue lymphangiogenesis (31). In the developing trachea, the emergence of LYVE-1- macrophages preceded that of LYVE-1+ macrophages, and most LYVE-1+ macrophages were present in vascularized areas (Fig. 4, A-C). Furthermore, c-fms expression was more abundant in LYVE-1+ than in LYVE-1- macrophages (Fig. 4 D). As it is likely that M-CSF/c-fms signaling contributes to lymphangiogenesis, we examined developing lymphatic structures in op/op mice. At P15, the number of LYVE-1- and LYVE-1+ macrophages dramatically decreased in the tracheas and ears of op/op mice, and reduced lymphatic branching was observed (Fig. 4, E-H, O, and P). Furthermore, tissue fluids drained more slowly in the limbs and ears of op/op mice (Fig. 4, I-L). By P15, some op/op mice exhibited apparent perforation of the dorsal tracheal surface (Fig. 4, E and F, insets), presumably as a result of abnormal lymphatic drainage. Although hydrocephalus is thought to underlie the high lethality of op/op mice at this stage (14), tracheal perforation could also lead to death. However, op/op mice that survived for 3 mo possessed normal lymphatic systems (unpublished data). The op/op mice exhibited normal embryonic lymphangiogenesis but lacked LYVE-1+ macrophages (Fig. 4, M and N; and ). Treatment with Ki20227 or anti-c-fms antibodies decreased both LYVE-1- and LYVE-1+ macrophages and reduced the extent of lymphatic branching (Fig. 4, R and S). Collectively, these data show that M-CSF contributes to the appearance of LYVE-1+ macrophages and postnatal lymphatic development.
###end p 15
###begin p 16
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M-CSF contributes to postnatal lymphatic development.</bold>
###xml 206 207 206 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 404 405 404 405 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 420 421 420 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 647 652 647 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 760 765 760 765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1003 1008 1003 1008 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1142 1147 1142 1147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 1216 1217 1216 1217 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1275 1276 1273 1274 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1320 1321 1318 1319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1337 1338 1335 1336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1608 1609 1606 1607 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1620 1621 1618 1619 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1764 1765 1760 1761 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1809 1810 1805 1806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 653 657 <span type="species:ncbi:10090">mice</span>
###xml 766 770 <span type="species:ncbi:10090">mice</span>
###xml 983 987 <span type="species:ncbi:10090">mice</span>
###xml 1009 1013 <span type="species:ncbi:10090">mice</span>
###xml 1148 1152 <span type="species:ncbi:10090">mice</span>
M-CSF contributes to postnatal lymphatic development. (A-C) Triple IHC of Mac-1 (green), LYVE-1 (red), and PECAM-1 (blue) in tracheas (representative images of four independent experiments). Note the LYVE-1+ macrophages in the vascularized area (arrows). (D) FACS analysis of dissociated cells (a representative plot of three independent experiments). Note the more abundant expression of c-fms in LYVE-1+ than in LYVE-1- macrophages. (E-H) Whole-mount IHC of Mac-1 (green), LYVE-1 (red), and PECAM-1 (blue) in P15 tracheas (E and F) or ears (G and H; representative images of six independent experiments). Note the reduced lymphatic branching in op/op mice. Insets in E and F indicate bright field views of P15 trachea. Note the perforation typically seen in op/op mice (arrowhead). (I-L) Lymphangiography in ears (I and K) and limbs (J and L; representative images of three independent experiments). Note that the blue dye (arrowheads) observed in the lymphatic ducts of wild-type mice is not seen in op/op mice. (M and N) Whole-mount IHC of LYVE-1 in the hearts of E17 embryos (representative images of three independent experiments). The op/op mice exhibited normal lymphangiogenesis, although they lacked LYVE-1+ macrophages. (O-Q) Quantification (mean +/- SD) of LYVE-1+ macrophages or lymphatic branching points (n = 6 [O and P]; n = 3 [Q]). (R) Triple IHC of Mac-1 (green), LYVE-1 (red), and PECAM-1 (blue) in P15 tracheas or ears systemically treated with vehicle (methylcellulose), Ki20227, control IgG, or anti-c-fms IgG during P8 and P15. Treatment with Ki20227 or anti-c-fms IgG decreased LYVE-1- and LYVE-1+ macrophages and reduced lymphatic branching (representative images of six independent experiments). (S) Quantification (mean +/- SD) of LYVE-1+ macrophages or lymphatic branching points (n = 6). Bars: (I-N) 200 microm; (A-C, E-H, and R) 50 microm. *, P < 0.05; **, P < 0.01.
###end p 16
###begin title 17
M-CSF inhibition selectively suppresses tumor angiogenesis and lymphangiogenesis
###end title 17
###begin p 18
###xml 128 129 128 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 131 132 131 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib2">2</xref>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">32</xref>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 575 578 575 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 566 578 566 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ink4a/ARF<sup>&#8722;/&#8722;</sup></italic>
###xml 797 808 797 808 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, A&#8211;E</xref>
###xml 1100 1119 1100 1119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, A&#8211;G and Q&#8211;T</xref>
###xml 1196 1217 1196 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, H&#8211;J, U, and V</xref>
###xml 1450 1461 1450 1461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, K&#8211;M</xref>
###xml 1566 1567 1566 1567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1661 1672 1661 1672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, N&#8211;P</xref>
###xml 1713 1715 1713 1715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 1885 1893 1885 1893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 W</xref>
###xml 381 386 <span type="species:ncbi:10090">mouse</span>
###xml 419 423 <span type="species:ncbi:10090">mice</span>
###xml 651 655 <span type="species:ncbi:10090">mice</span>
###xml 941 945 <span type="species:ncbi:10090">Mice</span>
###xml 1190 1194 <span type="species:ncbi:10090">mice</span>
###xml 1307 1311 <span type="species:ncbi:10090">mice</span>
###xml 1398 1402 <span type="species:ncbi:10090">mice</span>
###xml 1464 1468 <span type="species:ncbi:10090">Mice</span>
###xml 1655 1659 <span type="species:ncbi:10090">mice</span>
###xml 1748 1752 <span type="species:ncbi:10090">mice</span>
The mechanisms underlying developmental angiogenesis and lymphangiogenesis may impact tumor angiogenesis and lymphangiogenesis (1, 2, 32); thus, we hypothesized that M-CSF-targeted therapies selectively suppress tumor angiogenesis and lymphangiogenesis. These effects may be especially noticeable in osteosarcomas, which express high levels of M-CSF (33). Therefore, we analyzed a mouse model of osteosarcoma, in which mice were transplanted with a newly established osteosarcoma cell line, AX (unpublished data). This line was established from c-Myc-overexpressing Ink4a/ARF-/- BM-derived stromal cells transfected with EGFP. Tumors grew actively in mice subcutaneously inoculated with AX cells and were accompanied by intratumor high-density vascularization and abundant peritumoral lymphatics (Fig. 5, A-E). To analyze the effects of M-CSF inhibition, Ki20227 or anti-c-fms antibodies were administered via daily subcutaneous injections. Mice treated with Ki20227 or anti-c-fms antibodies exhibited suppressed tumor growth, dramatically decreased tumor vascularization and peritumoral lymphatics (Fig. 5, A-G and Q-T), and decreased BrdU incorporation by tumor cells relative to control mice (Fig. 5, H-J, U, and V). Although small calcified loci were detected at the center of tumors in vehicle-treated mice, early and massive calcified loci were detected throughout the transplanted tumors in mice treated with Ki20227 or anti-c-fms antibodies (Fig. 5, K-M). Mice treated with Ki20227 or anti-c-fms antibodies exhibited dramatically decreased peritumoral LYVE-1+ macrophages and perivascular macrophages infiltrated into tumors compared with control mice (Fig. 5, N-P). In contrast to VEGFR2 neutralization (11), continuous treatment of adult mice with Ki20227 or anti-c-fms antibodies for a period of 56 d did not affect healthy vascular and lymphatic systems outside the tumor (Fig. 5 W). Collectively, M-CSF inhibition selectively suppressed tumor angiogenesis and lymphangiogenesis.
###end p 18
###begin p 19
###xml 0 103 0 103 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M-CSF inhibition selectively suppresses tumor angiogenesis and lymphangiogenesis in mouse osteosarcoma.</bold>
###xml 270 271 268 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1102 1103 1100 1101 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1353 1354 1349 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1407 1408 1401 1402 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1411 1412 1405 1406 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1420 1421 1414 1415 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1739 1740 1733 1734 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1751 1752 1745 1746 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 84 89 <span type="species:ncbi:10090">mouse</span>
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 1652 1656 <span type="species:ncbi:10090">mice</span>
M-CSF inhibition selectively suppresses tumor angiogenesis and lymphangiogenesis in mouse osteosarcoma. (A and B) Typical appearance of mice 42 d after transplantation with AX cells. Arrows indicate tumor areas. (C and D) Quantification (mean +/- SD) of tumor diameter (n = 5). (E-G) An IHC analysis of PECAM-1 (green) and LYVE-1 (red) in tumors 21 d after transplantation (representative images of seven independent experiments). Arrowheads in E indicate peritumoral lymphatics. Treatment with Ki20227 or anti-c-fms IgG decreased the amount of associated vascularization and peritumoral lymphatics. (H-M) An IHC analysis using GFP (green) and BrdU (red; H-J) or Alizarin red staining (K-M; representative images of five independent experiments). Treatment with Ki20227 or anti-c-fms IgG decreased BrdU incorporation into tumor cells but increased tumor calcification (asterisks). (N-P) An IHC analysis of Mac-1 (green), PECAM-1 (blue), and LYVE-1 (red) in tumors 21 d after transplantation. Dotted lines indicate tumor margins. Treatment with Ki20227 or anti-c-fms IgG decreased the peritumoral LYVE-1+ macrophages (arrowheads) and perivascular macrophages (asterisks) into tumors (representative images of seven independent experiments). (Q-T) Quantification (mean +/- SD) of vascularized areas (Q and R) or peripheral areas with lymphatics (S and T; n = 7). (U and V) Quantification (mean +/- SD) of BrdU+GFP+ cells (n = 5). (W) An IHC analysis using the indicated antibodies for adult retina, trachea, or ears after 56 d of treatment (representative images of four independent experiments). No vascular and lymphatic abnormalities were observed in mice treated with Ki20227 or anti-c-fms IgG, although these treatments decreased LYVE-1- and LYVE-1+ macrophages. Bars: (W) 200 microm; (E-P) 50 microm. *, P < 0.05; **, P < 0.01.
###end p 19
###begin p 20
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 869 874 869 874 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csf-1</italic>
###xml 959 965 959 965 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csfr-1</italic>
We performed in vitro culture experiments to determine if the tumor-suppressing effects of c-fms inhibition are mediated by effects on tumors or on recruited monocytes. Hypoxic growth resulted in osteogenic differentiation and M-CSF expression and decreased proliferation in cultured AX cells (). However, supplementation with 100 nM Ki20227, a sufficient dose for the inhibition of c-fms kinase (27), did not affect osteogenic differentiation or proliferation in AX cells (Fig. S4, A and F). Supplementation with 100 nM Ki20227 inhibited survival and proliferation in cultured BM mononuclear cells (MNCs; unpublished data). To identify the potential ligand-receptor interactions resulting from M-CSF signaling between tumors and macrophages, we compared the expression of M-CSF and c-fms in cultured AX cells and in BM MNCs. Cultured AX cells exhibited high levels of csf-1 expression, compared with cultured MNCs (Fig. S4 D), but relatively lower levels of csfr-1 (Fig. S4 E) expression. These in vitro data suggest that the tumor-suppressing effects of M-CSF inhibition are mediated by effects on recruited macrophages but do not directly affect AX cells.
###end p 20
###begin title 21
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
M-CSF inhibition suppresses tumor metastasis of mouse osteosarcoma and improves prognosis
###end title 21
###begin p 22
###xml 398 415 398 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6, A&#8211;C and V</xref>
###xml 495 523 495 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6, D, G, J, M, P, and S</xref>
###xml 576 578 576 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 657 665 657 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 X</xref>
###xml 772 789 772 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6, D&#8211;U and W</xref>
###xml 834 842 834 842 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 X</xref>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 1010 1012 1010 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 1013 1015 1013 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 1188 1191 1188 1191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1179 1191 1179 1191 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegfr1 tk<sup>&#8722;/&#8722;</sup></italic>
###xml 246 250 <span type="species:ncbi:10090">mice</span>
###xml 392 396 <span type="species:ncbi:10090">mice</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 556 561 <span type="species:ncbi:9606">human</span>
###xml 602 606 <span type="species:ncbi:10090">mice</span>
###xml 720 724 <span type="species:ncbi:10090">mice</span>
###xml 810 814 <span type="species:ncbi:10090">mice</span>
###xml 1087 1092 <span type="species:ncbi:10090">mouse</span>
###xml 1139 1143 <span type="species:ncbi:10090">mice</span>
We then examined the effects of Ki20227 and anti-c-fms antibodies on tumor metastasis and disease prognosis. We performed a functional analysis of tumor-associated lymphatics by examining the dye efflux capacity of transplanted tumors. Tumors in mice treated with Ki20227 or anti-c-fms antibodies exhibited significantly higher levels of dye retention compared with tumors in vehicle-treated mice (Fig. 6, A-C and V). In vehicle-treated mice, transplanted AX cells spread to the liver and lung (Fig. 6, D, G, J, M, P, and S), two major metastatic sites in human osteosarcoma (20). Approximately 20% of mice remained alive 56 d after tumor cell inoculation (Fig. 6 X). However, metastases were dramatically suppressed in mice treated with Ki20227 or anti-c-fms antibodies (Fig. 6, D-U and W), and >90% of these mice survived for 56 d (Fig. 6 X). Aside from its role in M-CSF/c-fms signaling, VEGF/Flt1 plays a profound role in the recruitment of macrophages and the progression of cancer in various models (11, 34-36). To examine the involvement of VEGF/Flt1 signaling in our established mouse osteosarcoma, AX cells were transplanted into mice deficient in Flt1 tyrosine kinase (Vegfr1 tk-/-). Deficiency in Flt1 tyrosine kinase did not affect the number of recruited macrophages (), tumor growth (Fig. S5 C), or metastasis (Fig. S5, D-G), suggesting that macrophages are less dependent on VEGF/Flt1 signaling in this model than in other cancer models.
###end p 22
###begin p 23
###xml 0 90 0 90 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M-CSF inhibition suppresses tumor metastasis of mouse osteosarcoma and improves prognosis.</bold>
###xml 695 696 693 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 743 744 741 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
###xml 540 544 <span type="species:ncbi:10090">mice</span>
###xml 571 575 <span type="species:ncbi:10090">mice</span>
###xml 786 790 <span type="species:ncbi:10090">mice</span>
M-CSF inhibition suppresses tumor metastasis of mouse osteosarcoma and improves prognosis. (A-C) Representative appearance of tumors 2 h after injection with Evans blue dye (representative images of five independent experiments). (D-U) Fluorescent views (D-F and M-O), IHC for GFP (green) and TOTO3 (blue; G-I and P-R), or hematoxylin and eosin staining (J-L and S-U) in the liver or lung 56 d after tumor inoculation (representative images of five independent experiments). Note that the multiple metastatic masses (arrowheads) in control mice were completely absent in mice treated with Ki20227/anti-c-fms IgG. (V-X) Quantification (mean +/- SD) of the OD600 measurements of extracted dye (V; n = 5), liver and lung metastasis at day 56 (W; n = 5), and survival rate (X; at least six mice were examined in each group). Bars, 200 microm. *, P < 0.05; **, P < 0.01.
###end p 23
###begin title 24
M-CSF inhibition disorganizes extracellular matrices and suppresses tumor progression when treatment is interrupted
###end title 24
###begin p 25
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 377 388 377 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, A&#8211;F</xref>
###xml 495 506 495 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, G&#8211;L</xref>
###xml 661 676 661 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, M and N</xref>
###xml 709 712 709 712 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 833 848 833 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, O and P</xref>
###xml 1247 1255 1247 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7 Q</xref>
###xml 1487 1498 1487 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, S&#8211;U</xref>
###xml 1600 1611 1600 1611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, V&#8211;X</xref>
###xml 1811 1831 1811 1831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7, Y, Z, and AA</xref>
###xml 489 493 <span type="species:ncbi:10090">mice</span>
###xml 713 717 <span type="species:ncbi:10090">mice</span>
###xml 827 831 <span type="species:ncbi:10090">mice</span>
To explore the differences between M-CSF inhibition and VEGF inhibition, we compared the antitumor effects of two small tyrosine kinase inhibitors, Ki20227 and SU1498. Vascular ECM structures stained by fibronectin (which has the potential to induce tumor vascular regrowth) (8) retained the spatial distribution surrounding endothelial cells treated with SU1498 or a vehicle (Fig. 7, A-F). In contrast, these structures were irregularly deposited throughout the tumors in Ki20227-treated mice (Fig. 7, G-L), suggesting a disturbance in the remodeling or degradation of ECM scaffolds. In contrast to Ki20227, SU1498 did not affect tumor-associated macrophages (Fig. 7, M and N). Tumors transplanted into MMP-9-/- mice exhibited irregularly deposited ECM structures, which is similar to tumors transplanted into Ki20227-treated mice (Fig. 7, O and P), and exhibited decreased tumor growth (not depicted). These data suggest that the proteases produced by macrophages contribute to matrix remodeling. Furthermore, we compared the antitumor effects of M-CSF inhibition and VEGF inhibition in three differential therapeutic protocols, including the protocol that involved interruption of administration in addition to vehicle or continuous treatment (Fig. 7 Q). Although continuous SU1498 administration greatly inhibited tumor growth and vascular/lymphatic growth in tumors, as did Ki20227 administration, interruption of SU1498 treatment resulted in rapid vascular and lymphatic regrowth (Fig. 7, S-U). In contrast, interruption of Ki20227 administration greatly reduced vascular and lymphatic growth (Fig. 7, V-X). Although the interruption of SU1498 treatment did not sufficiently inhibit tumor metastasis and cancer death, sustained effectiveness was observed after the interruption of Ki20227 administration (Fig. 7, Y, Z, and AA).
###end p 25
###begin p 26
###xml 0 116 0 116 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">M-CSF inhibition disorganizes extracellular matrices and suppresses tumor progression when treatment is interrupted.</bold>
###xml 735 736 735 736 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 746 747 746 747 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 839 842 839 842 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 834 842 834 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9<sup>+/+</sup></italic>
###xml 851 854 851 854 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 846 854 846 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9<sup>&#8722;/&#8722;</sup></italic>
###xml 1003 1006 1003 1006 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 998 1006 998 1006 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9<sup>&#8722;/&#8722;</sup></italic>
###xml 2153 2154 2149 2150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 396 400 <span type="species:ncbi:10090">mice</span>
###xml 427 431 <span type="species:ncbi:10090">mice</span>
###xml 477 481 <span type="species:ncbi:10090">mice</span>
###xml 855 859 <span type="species:ncbi:10090">mice</span>
###xml 1007 1011 <span type="species:ncbi:10090">mice</span>
###xml 1281 1285 <span type="species:ncbi:10090">mice</span>
###xml 2196 2200 <span type="species:ncbi:10090">mice</span>
M-CSF inhibition disorganizes extracellular matrices and suppresses tumor progression when treatment is interrupted. (A-L) An IHC analysis of PECAM-1 (green) and fibronectin (red) in tumors 21 d after transplantation (representative images of three independent experiments). Note that massively deposited fibronectin proteins were distributed throughout the tumors (asterisks) in Ki20227-treated mice but not in SU1498-treated mice, whereas tumor vasculature decreased in both mice. (M and N) An IHC analysis of Mac-1 (green), PECAM-1 (blue), and LYVE-1 (red) in tumors 21 d after transplantation (representative images of three independent experiments). Dotted lines indicate tumor margins. Treatment with SU1498 did not affect LYVE-1- or LYVE-1+ macrophages. (O and P) Fibronectin staining of tumors 21 d after transplantation into MMP-9+/+ or MMP-9-/- mice (representative images of three independent experiments). Note the presence of massively deposited fibronectin proteins (asterisk) in the MMP-9-/- mice. (Q) A modified scheme involving the administration of small molecule inhibitors. Administration was either continuous for 56 d (continuous) or terminated at day 21 (interrupt) after tumor inoculation. (R) Quantification (mean +/- SD) of tumor diameter (more than five mice were examined in each regimen). (S-X) An IHC analysis of PECAM-1 (green) and LYVE-1 (red) in tumors 21 d after transplantation (representative images of three independent experiments). Although continuous SU1498 administration greatly inhibited vascular and lymphatic growth, interruption of treatment resulted in rapid vascular (asterisk) and lymphatic (arrows) regrowth. In contrast, Ki20227 reduced vasculature and lymphatics even after the interruption of treatment. (Y) Fluorescent views of liver or lung at day 56 in each regimen (representative images of five independent experiments). Although the interruption of SU1498 treatment caused multiple tumor metastases (as in vehicle treatment), metastatic masses were greatly reduced when Ki20227 treatment was interrupted. (Z) Quantification (mean +/- SD) of liver and lung metastases at day 56 in each regimen (n = 5). (AA) Survival rate (more than five mice were examined in each regimen). Bars: (Y) 1 mm; (A-P and S-X) 50 microm. *, P < 0.05; **, P < 0.01.
###end p 26
###begin title 27
DISCUSSION
###end title 27
###begin p 28
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 14 18 <span type="species:ncbi:10090">mice</span>
###xml 356 360 <span type="species:ncbi:10090">mice</span>
We used op/op mice to demonstrate that M-CSF-dependent macrophages contribute to both vascular and lymphatic development. Furthermore, we show that M-CSF is required for pathological neovascularization but not for the recovery of normal vasculature in OIR. Deficiency in M-CSF does not affect the maintenance of stable adult vasculature and lymphatics. In mice with osteosarcoma, M-CSF inhibition selectively suppressed tumor angiogenesis and lymphangiogenesis and decreased tumor regrowth after the interruption of treatment.
###end p 28
###begin p 29
###xml 236 241 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 665 666 665 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 1058 1059 1058 1059 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1062 1063 1062 1063 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1079 1081 1079 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 1166 1174 <span type="species:ncbi:9606">patients</span>
Our data showing the highly specific effects of M-CSF inhibition on pathological angiogenesis and lymphangiogenesis are supported by the observation that no detectable abnormalities in adult vascular and lymphatic systems were found in op/op mice. In contrast to the effects of VEGF blockade, interruption of M-CSF inhibition did not promote rapid tumor regrowth but rather improved the prognosis relative to treatment with a vehicle. This difference might be a result of the effects of M-CSF inhibition on the "sleeves" of the basement membrane. These so-called sleeves are conserved during VEGF blockade and assist with rapid vascular regrowth in primary tumors (8). The physiological role of retinal macrophages in developmental vascular remodeling, but not in angiogenic sprouting, suggests that M-CSF inhibition and VEGF blockade target different factors. Indeed, the tumor-suppressive effects of M-CSF inhibition are independent of VEGF signaling. Furthermore, a recent study showed that tumor refractoriness to anti-VEGF treatment is mediated by Mac-1+Gr1+ myeloid cells (37), suggesting that M-CSF-targeted therapy may serve as a useful secondary therapy in patients who are resistant to VEGF blockade.
###end p 29
###begin p 30
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 699 704 699 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 856 858 856 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 875 878 875 878 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1247 1249 1247 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">38</xref>
###xml 1407 1412 1407 1412 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 705 709 <span type="species:ncbi:10090">mice</span>
###xml 879 883 <span type="species:ncbi:10090">mice</span>
###xml 1126 1132 <span type="species:ncbi:9606">humans</span>
We showed that retinal macrophages express high levels of MMP-2 and MMP-9 but not VEGF. These expression patterns are thought to reflect the vascular defects in op/op mice, which are characterized by normal sprouting angiogenesis and impaired vascular remodeling. Although VEGF plays a critical role in angiogenic sprouting (26), MMP-2 and MMP-9 are gelatinase proteinases with overlapping substrates (e.g., fibronectin) that function together in some situations such as aortic aneurysms (24). One of the major questions in our study is whether disordered fibronectin architecture, which is presumably caused by the absence of macrophage MMP-2 and MMP-9, is the primary cause of vascular defects in op/op mice. However, the precise function of specific proteinases is generally difficult to discern because of the considerable redundancy of these enzymes (24). In fact, MMP-9-/- mice exhibit normal vascular development and normal ECM structures in their developing retina (unpublished data), which is in contrast to the dramatically decreased NVTs observed in the OIR model. Clinical observations of diabetic microvessels in humans have revealed that disordered fibronectin structures are the earliest events preceding various capillary defects (38). These observations also support the idea that disordered fibronectin architecture accounts for defects associated with impaired vascular remodeling in the op/op retina.
###end p 30
###begin p 31
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 176 177 176 177 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 235 240 235 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 285 286 285 286 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 359 360 359 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 504 505 504 505 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 519 521 519 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 523 525 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 527 529 527 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">32</xref>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">39</xref>
###xml 241 245 <span type="species:ncbi:10090">mice</span>
Previous studies have shown that M-CSF/c-fms signaling promotes the differentiation of circulating monocytes into macrophages (13). However, abundant c-fms expression by LYVE-1+ macrophages and defective postnatal lymphangiogenesis in op/op mice suggests that M-CSF also acts on LYVE-1+ macrophages and lymphangiogenesis. The link between the absence of LYVE1+ cells and reduced lymphangiogenesis may be explained by reductions in the secretion of VEGF-C, VEGF-D, or other inflammatory cytokines by LYVE1+ macrophages (11, 31, 32). The significant contribution of BM-derived lymphatic endothelial progenitor cells to lymphangiogenesis (39) may be responsible for this link.
###end p 31
###begin p 32
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib11">11</xref>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 169 171 169 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 516 519 516 519 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 507 519 507 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegfr1 tk<sup>&#8722;/&#8722;</sup></italic>
###xml 754 757 754 757 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 745 757 745 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegfr1 tk<sup>&#8722;/&#8722;</sup></italic>
###xml 265 270 <span type="species:ncbi:9606">human</span>
###xml 520 524 <span type="species:ncbi:10090">mice</span>
###xml 758 762 <span type="species:ncbi:10090">mice</span>
Other than M-CSF/c-fms signaling, VEGF/Flt1 signaling significantly contributes to the recruitment of macrophages and tumor progression in various cancer models (11, 34-36). In our osteosarcoma model (in which tumor cells expressed high levels of M-CSF, just as in human osteosarcoma), deficiency in Flt1 tyrosine kinase did not significantly affect tumor progression. These data suggest that tumor progression depends primarily on M-CSF/c-fms signaling rather than on VEGF/Flt1 signaling. In addition, the Vegfr1 tk-/- mice in the OIR model did not experience a significant reduction in the amount of NVT or in the number of recruited macrophages (unpublished data). However, decreases in the number of tumor-associated macrophages observed in Vegfr1 tk-/- mice in other cancer models suggest that VEGF/Flt1 signaling plays an important role in the recruitment of macrophages and that Flt1-targeted therapy also holds potential as a tumor-selective strategy. It would be interesting to determine the extent to which M-CSF/c-fms or VEGF/Flt1 signaling affects macrophage recruitment in various other cancer models.
###end p 32
###begin p 33
###xml 119 123 <span type="species:ncbi:10090">mice</span>
Overall, our data show that M-CSF inhibition efficiently suppresses pathological angiogenesis and lymphangiogenesis in mice with ischemic retinopathy and osteosarcoma. This highly selective chemotherapy, which does not affect healthy tissues or induce toxic side effects, may be an ideal treatment for ocular neovascular diseases and cancer.
###end p 33
###begin title 34
MATERIALS AND METHODS
###end title 34
###begin title 35

###end title 35
###begin title 36
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice and hyperoxia exposure.
###end title 36
###begin p 37
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 78 81 78 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 126 129 126 129 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 117 129 117 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegfr1 tk<sup>&#8722;/&#8722;</sup></italic>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">35</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
###xml 606 608 606 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 12 16 <span type="species:ncbi:10090">mice</span>
###xml 42 46 <span type="species:ncbi:10090">mice</span>
###xml 82 86 <span type="species:ncbi:10090">mice</span>
###xml 130 134 <span type="species:ncbi:10090">mice</span>
###xml 334 338 <span type="species:ncbi:10090">mice</span>
###xml 482 486 <span type="species:ncbi:10090">mice</span>
The C57BL/6 mice (Japan SLC, Inc.), op/op mice (The Jackson Laboratory), MMP-9-/- mice (The Jackson Laboratory), and Vegfr1 tk-/- mice (34, 35) were used. All animal experiments were approved by Keio University and were performed in accordance with the Guidelines of Keio University for Animal and Recombinant DNA experiments. The P8 mice and nursing mothers used in the OIR model were maintained for 3 d in 85% oxygen and then placed in room air (40). To examine c-fms inhibition, mice were subcutaneously injected once daily from P8 to P11 or from P11 to P16 with 50 mg/kg (body weight [BW]) of Ki20227 (27) dissolved in 100 microl methylcellulose or vehicle.
###end p 37
###begin title 38
Preparation of whole-mount samples.
###end title 38
###begin p 39
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
Isolated eyes, tracheas, and other tissues were fixed for 20 min in 4% paraformaldehyde (PFA) in PBS and dissected as previously described (31, 40). Tissues were postfixed and stored in methanol at -20degreesC. The tissue samples were gradually rehydrated for further analysis.
###end p 39
###begin title 40
Whole-mount IHC and ISH.
###end title 40
###begin p 41
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 79 81 79 81 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
IHC analysis of whole-mount samples was performed as previously described (31, 40). For whole-mount retinal ISH, retinas were briefly digested with proteinase K and hybridized with digoxigenin-labeled antisense RNA probes.
###end p 41
###begin title 42
Antibodies for IHC.
###end title 42
###begin p 43
###xml 82 85 <span type="species:ncbi:10116">rat</span>
Primary monoclonal antibodies used include hamster anti-PECAM-1 (2H8; Millipore), rat anti-PECAM-1 (MEC13.3; BD), Mac-1 (M1/7; BD), F4/80 (A3-1; AbD Serotec), PDGFR-alpha (APA5; eBioscience), and desmin (Dako). Primary polyclonal antibodies included Alexa Fluor 488-conjugated anti-GFP (Invitrogen), MMP-9 (Santa Cruz Biotechnology, Inc.), collagen IV (Cosmo Bio), LYVE-1 (ReliaTech), and fibronectin (Dako). Secondary antibodies included Alexa Fluor 488 fluorescence-conjugated IgGs (Invitrogen) or Cy3/Cy5-conjugated IgGs (Jackson ImmunoResearch Laboratories). In preparation for nuclear staining, specimens were treated with TOTO3 (Invitrogen) or DAPI (Invitrogen). In some experiments, blood vessels and monocyte lineage cells were simultaneously visualized using biotinylated isolectin B4 (Sigma-Aldrich), followed by treatment with fluorescent streptavidin conjugates (Invitrogen).
###end p 43
###begin title 44
Tumor inoculation and c-fms inhibitor treatment.
###end title 44
###begin p 45
###xml 109 110 109 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 365 367 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 586 588 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 833 834 801 802 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
###xml 436 439 <span type="species:ncbi:10116">rat</span>
###xml 456 462 <span type="species:ncbi:10090">murine</span>
###xml 653 656 <span type="species:ncbi:10116">rat</span>
The AX cells were cultured in DMEM containing 10% FCS, and the medium was changed daily. Approximately 2 x 106 cells in subconfluent culture were resuspended in 200 microl of medium and were subcutaneously transplanted into the back of mice. The following was injected daily into subcutaneous tissues at the base of the tail: approximately50 mg/kg (BW) of Ki20227 (27) dissolved in 200 microl methylcellulose; 50 mg/kg (BW) of AFS98, a rat monoclonal anti-murine c-fms antibody (IgG2a; provided by S.-I. Nishikawa and S. Nishikawa, Riken Center for Developmental Biology, Kobe, Japan) (28), dissolved in 200 microl of PBS; an isotype-matched irrelevant rat IgG dissolved in 200 microl of PBS; 9 mg/kg (BW) of SU1498 (EMD) dissolved in 100 microl of DMSO; or vehicle only. Metastatic lesions were enumerated by counting detectable GFP+ masses under a fluorescent microscope.
###end p 45
###begin title 46
Intraocular injections.
###end title 46
###begin p 47
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib26">26</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
###xml 168 171 <span type="species:ncbi:10116">rat</span>
Injections into the vitreous body were performed using 33-gauge needles, as described previously (26, 40). Approximately 1 mg/ml AFS98 or an isotype-matched irrelevant rat IgG dissolved in approximately50 nl of sterile PBS was injected on P1 or P12 (OIR).
###end p 47
###begin title 48
Lymphangiography.
###end title 48
###begin p 49
Functional lymphatic vessels were visualized by injecting 20 microl of Evans blue dye (5 mg/ml; Sigma-Aldrich) into the hindlimb footpad or the ear, and lymphatic vessels were analyzed via light microscopy. In preparation for the tumor dye efflux experiment, we injected 50 microl of Evans blue dye into tumors and sacrificed animals 2 h later. Approximately 100 mg of tumors were dissected and incubated in 1 ml formamide (to extract the Evans blue dye), and the absorbency was measured at OD600 using a spectrophotometer.
###end p 49
###begin title 50
Quantitative RT-PCR analysis.
###end title 50
###begin p 51
###xml 296 301 296 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csf-1</italic>
###xml 319 325 319 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">csfr-1</italic>
###xml 346 352 346 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vegf-a</italic>
###xml 372 377 <span type="species:ncbi:10090">mouse</span>
Total RNA was prepared from cultured cells and reverse transcribed using Superscript II (Invitrogen). Quantitative PCR was performed on an ABI 7500 Fast Real-Time PCR system using the TaqMan Fast Universal PCR master mix (Applied Biosystems) and a TaqMan Gene Expression Assay mixture containing csf-1 (Mm00432688_m1), csfr-1 (Mm00432689_m1), or vegf-a (Mm00437304_m1). A mouse beta-actin (Mm00607939_s1) mixture served as an endogenous control. Data were analyzed using 7500 Fast System SDS Software 1.3.1. All experiments were performed in quadruplicate and a mean was obtained for each sample.
###end p 51
###begin title 52
FACS analysis.
###end title 52
###begin p 53
###xml 93 94 87 88 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 101 125 95 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Clostridium histolyticum</italic>
###xml 101 125 <span type="species:ncbi:1498">Clostridium histolyticum</span>
Dissected tracheas were incubated at 37degreesC for 30 min in DMEM containing 1% collagenase d (from Clostridium histolyticum; Roche) before dissociation by gentle trituration. Harvested cells were immunostained, followed by purification and analysis using the FACSVantage (BD).
###end p 53
###begin title 54
Confocal microscopy.
###end title 54
###begin p 55
Fluorescence images were obtained using a confocal laser-scanning microscope (FV1000; Olympus). Scanning was performed in sequential laser emission mode to avoid scanning at other wavelengths. Cells or substances of interest were quantified in eight (200 microm x 200 microm) fields of view per sample in each scanned image, and the mean of eight fields was determined.
###end p 55
###begin title 56
Statistical analysis.
###end title 56
###begin p 57
###xml 107 108 105 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Results were expressed as means +/- SD. The means of two groups were compared using a two-tailed Student's t test. P-values <0.05 were considered statistically significant.
###end p 57
###begin title 58
Online supplemental material.
###end title 58
###begin p 59
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 221 226 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 282 283 282 283 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 489 498 489 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegfr1 tk</italic>
###xml 498 501 498 501 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/+</sup>
###xml 515 518 515 518 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 506 518 506 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vegfr1 tk<sup>&#8722;/&#8722;</sup></italic>
###xml 49 53 <span type="species:ncbi:10090">mice</span>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
Fig. S1 shows normal vascular structure in op/op mice at P8 and P90. Fig. S2 shows that M-CSF deficiency or M-CSF inhibition does not affect vaso-obliteration in OIR model. Fig. S3 shows that various embryonic tissues in op/op mice exhibit normal lymphangiogenesis but lacked LYVE-1+ macrophages. Fig. S4 shows that hypoxia, but not Ki20227, induces osteogenic differentiation and decreases proliferation in cultured AX cells. Fig. S5 shows that there is no significant difference between Vegfr1 tk+/+ and Vegfr1 tk-/- in tumor progression when transplanted with AX cells. Online supplemental material is available at .
###end p 59
###begin title 60
Supplementary Material
###end title 60
###begin title 61
[Supplemental Material Index]
###end title 61
###begin p 62
We would like to thank Holger Gerhardt (Vascular Biology Laboratory, London Research Institute, UK), Donald M. McDonald (Cardiovascular Research Institute, University of California, San Francisco), and Takeshi Miyamoto (Keio University) for their helpful discussions and critical review of our manuscript. AFS98 was kindly provided by Shin-Ichi Nishikawa and Satomi Nishikawa (Riken Center for Developmental Biology, Kobe, Japan).
###end p 62
###begin p 63
This work was supported by Grants-in-Aid for Specially Promoted Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, by a grant from the Mitsubishi Pharma Research Foundation, by a grant from the Tokyo Biochemical Research Foundation, and by the Keio Kanrinmaru Project.
###end p 63
###begin p 64
The authors have no conflicting financial interests.
###end p 64
###begin article-title 65
Angiogenesis in life, disease and medicine.
###end article-title 65
###begin article-title 66
Angiogenesis as a therapeutic target.
###end article-title 66
###begin article-title 67
VEGF trap as a novel antiangiogenic treatment currently in clinical trials for cancer and eye diseases, and VelociGene-based discovery of the next generation of angiogenesis targets.
###end article-title 67
###begin article-title 68
VEGF-Trap: a VEGF blocker with potent antitumor effects.
###end article-title 68
###begin article-title 69
Anti-VEGF therapy: comparison of current and future agents.
###end article-title 69
###begin article-title 70
VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma.
###end article-title 70
###begin article-title 71
Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition.
###end article-title 71
###begin article-title 72
Rapid vascular regrowth in tumors after reversal of VEGF inhibition.
###end article-title 72
###begin article-title 73
Double target for tumor mass destruction.
###end article-title 73
###begin article-title 74
Bv8 regulates myeloid-cell-dependent tumour angiogenesis.
###end article-title 74
###begin article-title 75
Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.
###end article-title 75
###begin article-title 76
The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1.
###end article-title 76
###begin article-title 77
###xml 130 135 <span type="species:ncbi:10090">mouse</span>
Role of colony stimulating factor-1 in the establishment and regulation of tissue macrophages during postnatal development of the mouse.
###end article-title 77
###begin article-title 78
###xml 73 78 <span type="species:ncbi:10090">mouse</span>
Osteopetrosis, a new recessive skeletal mutation on chromosome 12 of the mouse.
###end article-title 78
###begin article-title 79
###xml 48 53 <span type="species:ncbi:10090">mouse</span>
Macrophages regulate the angiogenic switch in a mouse model of breast cancer.
###end article-title 79
###begin article-title 80
Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.
###end article-title 80
###begin article-title 81
###xml 115 120 <span type="species:ncbi:9606">human</span>
###xml 149 153 <span type="species:ncbi:10090">mice</span>
Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice.
###end article-title 81
###begin article-title 82
###xml 65 70 <span type="species:ncbi:9606">human</span>
Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts.
###end article-title 82
###begin article-title 83
Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach.
###end article-title 83
###begin article-title 84
Osteosarcoma: Oncologic and functional results. A single institutional report covering 22 years.
###end article-title 84
###begin article-title 85
Retinal angiogenesis in development and disease.
###end article-title 85
###begin article-title 86
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis.
###end article-title 86
###begin article-title 87
Development of the retinal vasculature.
###end article-title 87
###begin article-title 88
How matrix metalloproteinases regulate cell behavior.
###end article-title 88
###begin article-title 89
WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature.
###end article-title 89
###begin article-title 90
VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia.
###end article-title 90
###begin article-title 91
A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
###end article-title 91
###begin article-title 92
Functional hierarchy of c-kit and c-fms in intramarrow production of CFU-M.
###end article-title 92
###begin article-title 93
###xml 34 39 <span type="species:ncbi:10090">mouse</span>
Oxygen-induced retinopathy in the mouse.
###end article-title 93
###begin article-title 94
The pathogenesis of diabetic retinopathy: old concepts and new questions.
###end article-title 94
###begin article-title 95
Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation.
###end article-title 95
###begin article-title 96
###xml 37 42 <span type="species:ncbi:9606">human</span>
Lymphangiogenesis in development and human disease.
###end article-title 96
###begin article-title 97
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
###end article-title 97
###begin article-title 98
VEGFR1 tyrosine kinase signaling promotes lymphangiogenesis as well as angiogenesis indirectly via macrophage recruitment.
###end article-title 98
###begin article-title 99
Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis.
###end article-title 99
###begin article-title 100
Flt-1 signaling in macrophages promotes glioma growth in vivo.
###end article-title 100
###begin article-title 101
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.
###end article-title 101
###begin article-title 102
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Fibronectin overexpression in retinal microvessels of patients with diabetes.
###end article-title 102
###begin article-title 103
###xml 82 87 <span type="species:ncbi:9606">human</span>
Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants.
###end article-title 103
###begin article-title 104
###xml 107 111 <span type="species:ncbi:10090">mice</span>
Leukemia inhibitory factor regulates microvessel density by modulating oxygen-dependent VEGF expression in mice.
###end article-title 104
###begin p 105
###xml 252 257 252 257 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">op/op</italic>
###xml 259 272 259 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">osteopetrotic</italic>
Abbreviations used: BW, body weight; ECM, extracellular matrix; IHC, immunohistochemistry; ISH, in situ hybridization; M-CSF, macrophage CSF; MMP, matrix metalloproteinase; MNC, mononuclear cell; NVT, neovascular tuft; OIR, oxygen-induced retinopathy; op/op, osteopetrotic; VEGF, vascular endothelial growth factor.
###end p 105

